ELGEKA S.A.
DISTRIBUTION AGREEMENT BETWEEN ELGEKA S.A. AND SOLID S.A. 2) CHANGE IN THE SHARE CAPITAL OF MEDIHELM PHARMACEUTICAL S.A. AND SAMBROOK PHARMACEUTICAL S.A.
ELGEKA S.A. would like to notify the investing public that today, on the 1st of April 2008, has signed an agreement with the company SOLID S.A. for the exclusive distribution, sale, merchandising and Logistics of all the products of the latter company. The distribution will be realized in every channel throughout the Greek territory.
The company SOLID S.A. is situated at Avlona Attikis and is the exclusive importer in Greece and Cyprus of the dried fruits and other relative products under the brand FELIX. SOLID, from the beginning of the year, has successfully introduced them and already placed them to the largest super market chains in Greece.
The duration of the agreement is three years starting on the 01st of April 2008 until 31st of March 2011 (initial duration).
ELGEKA S.A. would also like to notify the investing public that today, the Extraordinaries General Assemblies of the companies MEDIHELM PHARMACEUTICAL S.A. (subsidiary of ELGEKA S.A. by 51%) and SAMBROOK PHARMACEUTICAL S.A. (which is controlled by ELGEKA S.A. with indirect participation of 45% and directly from Alexander Katsiotis by 6%) have assembled with a single subject in their agenda Reduction with a parallel increase of the Share Capital through new contribution in cash and the following decisions were taken:
a) The company MEDIHELM PHARMACEUTICAL S.A. decided the reduction of its Share Capital by ? 438.000 through a reduction in the par value of the share from ? 100 to ? 40 in order to capitalize the losses occurred at previous results, and a parallel increase of the Share Capital by ? 1.400.000 through the issuance of 35.000 new common shares, at a par value of ? 40 each. After the above decision the Share Capital will amount to ? 1.692.000 divided into 42.300 common shares, at a par value ? 40 each.
The other shareholder declared her intention not to participate to the above mentioned increase of MEDIHELM' s Share Capital, thus ELGEKA S.A. will cover in whole the Share Capital Increase and will own 91,54% from 51% which was its former participation.
b) The company SAMBROOK PHARMACEUTICAL S.A. decided the reduction of its Share Capital by euro 150.000 through a reduction in the par value of the share from euro 30 to euro 15 in order to cover part of the losses occurred at previous results and a parallel increase of the Share Capital by euro 802.500 through the issuance of 53.500 new common shares, at a par value euro 15 each. After the above decision the Share Capital of SAMBROOK PHARMACEUTICAL S.A. will amount to euro 952.500 divided into 63.500 common shares at a par value euro 15 each.
Finally, the other shareholders declared that they do not intent to exercise their participation right in the above mentioned Share Capital Increase of SAMBROOK, thus ELGEKA S.A. will cover in whole the Share Capital increase, and will own 91,34% of the company from 45% which was its former participation.
The company SOLID S.A. is situated at Avlona Attikis and is the exclusive importer in Greece and Cyprus of the dried fruits and other relative products under the brand FELIX. SOLID, from the beginning of the year, has successfully introduced them and already placed them to the largest super market chains in Greece.
The duration of the agreement is three years starting on the 01st of April 2008 until 31st of March 2011 (initial duration).
ELGEKA S.A. would also like to notify the investing public that today, the Extraordinaries General Assemblies of the companies MEDIHELM PHARMACEUTICAL S.A. (subsidiary of ELGEKA S.A. by 51%) and SAMBROOK PHARMACEUTICAL S.A. (which is controlled by ELGEKA S.A. with indirect participation of 45% and directly from Alexander Katsiotis by 6%) have assembled with a single subject in their agenda Reduction with a parallel increase of the Share Capital through new contribution in cash and the following decisions were taken:
a) The company MEDIHELM PHARMACEUTICAL S.A. decided the reduction of its Share Capital by ? 438.000 through a reduction in the par value of the share from ? 100 to ? 40 in order to capitalize the losses occurred at previous results, and a parallel increase of the Share Capital by ? 1.400.000 through the issuance of 35.000 new common shares, at a par value of ? 40 each. After the above decision the Share Capital will amount to ? 1.692.000 divided into 42.300 common shares, at a par value ? 40 each.
The other shareholder declared her intention not to participate to the above mentioned increase of MEDIHELM' s Share Capital, thus ELGEKA S.A. will cover in whole the Share Capital Increase and will own 91,54% from 51% which was its former participation.
b) The company SAMBROOK PHARMACEUTICAL S.A. decided the reduction of its Share Capital by euro 150.000 through a reduction in the par value of the share from euro 30 to euro 15 in order to cover part of the losses occurred at previous results and a parallel increase of the Share Capital by euro 802.500 through the issuance of 53.500 new common shares, at a par value euro 15 each. After the above decision the Share Capital of SAMBROOK PHARMACEUTICAL S.A. will amount to euro 952.500 divided into 63.500 common shares at a par value euro 15 each.
Finally, the other shareholders declared that they do not intent to exercise their participation right in the above mentioned Share Capital Increase of SAMBROOK, thus ELGEKA S.A. will cover in whole the Share Capital increase, and will own 91,34% of the company from 45% which was its former participation.